Antibodies targeting B-cell receptor complex membrane bound IGM and uses thereof
US9926381B2 · kind B2 · utility
1Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 1, 2014 |
| Grant date | Mar 27, 2018 |
| Priority date | — |
| Expiry date | Dec 13, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/77
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to monoclonal antibodies targeting the membrane bound IgM (mIgM) of the B-cell receptor complex found in B-cell lymphomas and leukemias. Monoclonal antibodies designated mAb4-2b, mAb1-1, mAb2-2b and mAb3-2b were produced by hybridoma cell lines (ATCC deposit no. PTA-121716), (ATCC deposit no. PTA-121719), (ATCC deposit no. PTA-121717), and (ATCC deposit no. PTA-121718), respectively. Another aspect of the present invention is the use of anti-B-Cell mIgM antibodies in the treatment of B-cell malignancies, including B-cell lymphomas and leukemias.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.